Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer's Disease

Stock Information for Annovis Bio Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Annovis Bio Inc.

Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer
Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants
Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants
Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results
Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026
Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio
Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission
Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.